OMB asks who can make the 86 essential medicines in the United States
Friday’s Federal Register notice is a request for information, not an award. Replies are due 26 October. It covers the finished dose, the active ingredient and the starting material, in the United States or near shore.
The Industrial Brief · Editorial · 26 September 2026 · 3 min
On Friday the Office of Management and Budget published a request for information in the Federal Register. It wants to know who has new or idle plant, in the United States or near shore, that can make finished doses, active ingredients and key starting materials for the 86 essential medicines on the ASPR list. Replies are due on 26 October 2026. The document is 2026-19646, at 91 FR 60983.
- 86
- Medicines on the ASPR list
- 26 Oct
- Replies close
- 91 FR 60983
- The notice
Bloomberg reported the same day that the administration wants those medicines made in the United States within 18 months, and that a committee will pick the strongest ideas from industry. That timeline is Bloomberg’s account. The notice itself is market research. It does not award a contract, and it does not name a plant.
OMB says the replies will be shared with federal agencies that buy essential medicines, or that are responsible for the domestic base for essential generic drugs. The list is the ASPR 86, from the first entry through voriconazole at number 86. The notice asks for capacity that exists or is idle. It does not order anyone to build it.
Get the Monday briefing
The week in manufacturing, for people who specify and buy. Eight minutes, before the first meeting.
SubscribeFurther reading
Now · Policy
France and Germany back a 90% car CO₂ cut for 2035 in return for tougher Made in Europe rules
The two governments want carmakers spared offsets for the last 10% of the 2035 target. In return, cars bought by public bodies or with public subsidies would have to pass a stricter Made in Europe test, and the UK could qualify on conditions.
The Industrial Brief · 17 Oct 2026 · 2 min
News · Policy
Reshoring a pharmaceutical plant takes years
Onshoring agreements can be signed in a quarter. Validated plants, qualified suppliers, and dual-sourced APIs cannot. The calendar is chemical, not political.
The Industrial Brief · 19 Sept 2026 · 5 min
News · Policy
US duties shut Indian solar plants out of their biggest export market
As China’s solar capex collapsed, India’s share of global manufacturing investment jumped. Preliminary US countervailing duties then shut the largest export market. Plant plans now need a different customer.
The Industrial Brief · 10 Sept 2026 · 5 min